Vensica is a transformative urology therapeutics brand that aims to unlock the potential of neurotoxins in the field of urology. They specialize in developing minimally invasive solutions using therapeutic ultrasound technology to deliver Botulinum Toxin A. Their flagship product, the Vibe System, offers a groundbreaking approach to urology drug delivery.

Vensica primarily focuses on addressing the needs of patients with bladder-related conditions such as Overactive Bladder, Neurogenic Bladder, and Painful Bladder Syndrome. They have successfully developed a proprietary device that enables needle-free and minimally invasive delivery of botulinum toxin A to the bladder. This innovative procedure eliminates the need for needles, anesthesia, and cystoscopy, making it simple and quick for both the urologist and the patient.

With a target market of over 4 million patients suffering from Overactive Bladder, 1. 5 million with Neurogenic Bladder, and 2 million with Painful Bladder Syndrome in the USA alone, Vensica's non-invasive solutions provide a crucial alternative for those who have failed oral medication treatments. Led by a team with extensive experience in entrepreneurship, including CEO Avner Geva, and supported by global corporate investors and VC's, Vensica is dedicated to revolutionizing urology therapeutics and improving the lives of millions of patients worldwide